About the Company
NEMUS Bioscience Inc. is a biopharmaceutical company focused on discovering, developing and commercializing new chemical entities from a class of chemically diverse compounds called cannabinoids. These molecules display pleiotropic activity by virtue of selectively binding to two types of cannabinoid receptors (CB1 and CB2 receptors) located throughout multiple organ systems in the body. NEMUS Bioscience Inc. is developing novel and proprietary classes of product candidates that are designed to improve therapeutic options through enhanced chemical engineering that allow drug candidates to have more predictable bioavailability and pharmacokinetics leading to optimized efficacy and safety.
NEMUS Bioscience Inc., a Nevada corporation is listed on the OTC Bulletin Board and trading under the symbol NMUS.
Nemus Bioscience Reports Favorable Bio-distribution and Anti-Addictive Findings Versus Plant-Derived Cannabidiol (CBD) in Animal Model Studies of NB2111, an Analogue of Cannabidiol
COSTA MESA, CA / ACCESSWIRE / February 13, 2017 / NEMUS Bioscience, Inc. (NMUS) announced that the company and its research and development partner, the University of Mississippi School of Pharmacy (UM), have conducted in vitro and in vivo...
Nemus Bioscience Announces Licensing Agreement with the University of Mississippi (UM) for a Cannabinoid-Based Anti-infective Platform Directed Against Drug-Resistant Organisms
COSTA MESA, CA / ACCESSWIRE / January 11, 2017 / NEMUS Bioscience, Inc. (NMUS) announced that the company had signed a licensing agreement with the University of Mississippi (UM) for a platform of cannabinoid-based molecules (UM5070) for potential anti-infective...
COSTA MESA, CA / ACCESSWIRE / January 10, 2017 / NEMUS Bioscience, Inc. (NMUS) today announced the closing of its Preferred Stock financing for gross proceeds of $1,200,000. Roth Capital Partners acted as the exclusive placement agent for the...
COSTA MESA, CA / ACCESSWIRE / December 29, 2016 / NEMUS Bioscience, Inc. (NMUS) today announced that it entered into a Securities Purchase Agreement with certain purchasers for the sale of up to 1,500 shares of Series D Preferred...